Invesco’s Matinas BioPharma MTNB Stock Holding History

Invesco’s Portfolio MTNB Stock Details MTNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-512	Closed	-$15K	–	3776
2018 Q4	$15K	Buy	512 +64	+14%	+$2.51K	﹤0.01%	3768
2018 Q3	$21K	Sell	448 -68	-13%	-$1.46K	﹤0.01%	3847
2018 Q2	$11K	Buy	+516	New	+$14.9K	﹤0.01%	3847

Other funds holding MTNB

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

GPCM

Granite Point Capital Management Boston, Massachusetts $4.9M AUM 38.41% 1-Year Est. Return

JGC

J. Goldman & Co New York $3.44B AUM 33.8% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Invesco's MTNB Position: Q1 2019 in Review

Invesco sold out of Matinas BioPharma (MTNB) in Q1 2019, closing a stake of 512 shares — an estimated $15K sold.

Invesco first reported a position in MTNB in Q2 2018 and held it in 3 quarters. The position peaked at $21K in Q3 2018. 54 funds tracked by Wall St. Rank hold MTNB as of Q1 2019.

Invesco reported no remaining Matinas BioPharma position as of Q1 2019 after selling out during the quarter.
Invesco sold 512 Matinas BioPharma shares in Q1 2019, an estimated $15K.
Invesco first reported a position in Matinas BioPharma in Q2 2018 and held it in 3 quarters.
Invesco's Matinas BioPharma position peaked at $21K in Q3 2018.
54 funds tracked by Wall St. Rank held Matinas BioPharma as of Q1 2019.

Based on Invesco's 13F filing for Q1 2019, filed 15 May 2019.